89 2021 ESG Report Transparency Appendices Responsible supply chain Product impact Climate change Introduction Healthy workforce and communities ESG issue Definition How we manage this issue Ethical Business Practices • Upholding and pr omoting high standards of ethics in business behavior. • Pr omoting ethical brand management and promotion, ethical marketing, and prevention of anti-competitive practices. • T raining associates on responsible interactions between company staff and healthcare professionals. • Engaging in sales and mark eting practices that incentivize ethical behaviors and promote truthful, non-misleading information in sales interactions with customers and the medical/ scientific community. • Impr oving Board structure and independence, executive compensation and accountability. Measuring sustainability strategy and business performance. • C omplying with state, federal and international laws pertaining to corruption and abuse, including anti-kickback laws and the U.S. Foreign Corrupt Practices Act. Refer to the Transparency section for further details on our Ethical Business Practice programs. Global Systemic Health Challenges • De veloping of treatments and medical devices that address widespread critical disease areas where there is unmet need and opportunity to prevent, diagnose and mitigate the impacts of global disease burdens, including delivering HIV/AIDS, malaria, maternal infant mortality and diabetes solutions. • A ddressing risks and opportunities that result from impacts caused by antimicrobial resistance (AMR) and continuing to prioritize AMR research and treatments with a focus on prevention, management and mitigation of disease impact. • A ddressing the risks and opportunities posed by the existing and emerging impacts that the climate has on human health. For details on how we are helping to address global systemic health challenges, including AMR, please refer to the Access to health section In March 2022, we launched BD Infectious Disease Insights to dig deeper into today’s most prominent infectious- disease trends. As part of our 2030+ commitments, we have set a goal to use our capabilities to contribute to solutions that address unmet climate-related health needs. We will provide details of progress in this area in future reports. Health Literacy and Adherence • P artnering with patients to promote their understanding of medical conditions or diseases and the reasons they are being treated, in order to improve patient outcomes through adherence to medication/treatment regimens. We provide various materials to help patients understand and manage their conditions, including web-based tools from: BD Life Sciences: Information is provided to patients about the BD Veritor™ At-Home COVID-19 Test at www.bdveritorathome.com . BD Interventional: Patients can understand and manage their Urinary Retention condition from the following websites: www.liberatormedical.com – This website provides consumers with tools to both understand their condition and choose the right product. www.purewickathome.com/ispurewickrightforme.html – This site includes information to help women who are suffering from urinary incontinence understand whether if the PureWick TM System is the right product for them. www.bardcare.com/consumers/get-answers/conditions/ – This site provides information for consumers on various conditions that the people we serve deal with on a daily basis.